Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC012F for Refractory Generalized Myasthenia Gravis
NCT06759948Phase 1Not yet recruiting
- Start
- Feb 2025
- Primary completion
- Feb 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC012 in myasthenia gravis (MG). Primary endpoints: Incidence of Dose-Limiting Toxicities at 28 days and Incidence and Severity of Adverse Events at 24 weeks. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
GC012
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06759948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06759948.